Saturday, March 7, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC, FDA, NIH workers did not report incidents of political interference, ‘fearing retaliation,’ government watchdog agency says

Just because incidents of political interference within the United States’ top health agencies are not reported, does not mean they don’t happen, a new federal report finds.

The US Government Accountability Office released a report Wednesday detailing how four public health agencies that were reviewed — the US Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health and the Office of the Assistant Secretary for Preparedness and Response — do not have procedures in place that define political interference in scientific decision-making. The report also recommends how such incidents of interference should be reported and addressed.

Yet the GAO report notes that employees at the CDC, FDA and NIH have revealed in interviews and via a confidential hotline that they observed incidences they perceived to be political interference but did not report them for various reasons: being unsure how to report the issue, believing that agency leaders already were aware of the incident and fearing retaliation.

“For example, in May 2020, a senior official from ASPR claimed HHS retaliated against him for disclosing, among other things, concerns about inappropriate political interference to make chloroquine and hydroxychloroquine available to the public as treatments for COVID-19,” GAO officials wrote in the report.

Source: CNN

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!